Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma (Q81433302)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

1 reference

central nervous system lymphoma

1 reference

primary central nervous system lymphoma

inferred from title

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

8

Lauren E Abrey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Fabio M Iwamoto

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jazmin Schwartz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Neeta Pandit-Taskar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Scott Peak

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Chaitanya R Divgi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

John Humm

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 December 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

2528-2534

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

An update on primary central nervous system lymphoma

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Treatment for primary CNS lymphoma: the next step

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Second-line treatment for primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

The Reference Man in diagnostic radiology dosimetry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Treatment of relapsed central nervous system lymphoma with high-dose methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23077

7 January 2021

Identifiers

DOI

10.1002/CNCR.23077

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17932895%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference